Background: Intra-amniotic inflammation with preterm premature rupture of membranes (PPROM) is a risk factor for fetal inflammatory response syndrome (FIRS) and adverse neonatal outcome. Objectives: To evaluate the diagnostic accuracy of lipopolysaccharide-binding protein (LBP) for detecting FIRS in preterm neonates born after PPROM. Methods: This was a prospective study in the level III neonatal intensive care unit (42 neonates; 23 + 6 to 31 + 6 weeks' gestation) of mothers with PPROM. Umbilical cord blood concentrations of LBP, C-reactive protein (CRP), interleukin (IL)-6 and white blood cell count with differential were measured at delivery and 24 h after birth. Neonates were classified into FIRS (n = 22) and no FIRS (n = 20) groups according to clinical criteria and IL-6 level (≥17.5 pg/ml). Histological examination of the placenta and umbilical cord was performed. Neurological examination at 12 months' corrected age was performed. Results: Umbilical cord blood concentration of LBP was significantly higher in the FIRS group than in the no FIRS group at delivery (median 21.6 mg/l vs. median 2.3 mg/l; p < 0.0001) and 24 h after birth (median 17.2 mg/l vs. median 20.0 mg/l; p < 0.001). The area under the ROC curve for FIRS at delivery was 0.98 (95% CI 0.88-1.0) for LBP, 0.92 (95% CI 0.80-0.99) for CRP and 0.82 (95% CI 0.64-0.94) for immature to total neutrophil ratio. Similar results were obtained if FIRS was defined by funisitis. Umbilical cord blood concentration of LBP at delivery was significantly higher in neonates with abnormal neurological exam at 12 months than in those with normal exam (median 19.5 mg/l vs. median 3.75 mg/l; p < 0.015). Conclusions: In preterm neonates born to asymptomatic women with PPROM, LBP in cord blood at delivery is an excellent diagnostic biomarker of FIRS/funisitis with prognostic potential.

Keywords:
Lipopolysaccharide-binding protein, Fetal inflammatory response syndrome, Interleukin-6, Funisitis, Preterm premature rupture of membranes, Prematurity
1.
Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM: The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998;179:194-202.
2.
Yoon BH, Romero R, Park JS, Kim M, Oh SY, Kim CJ, et al: The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. Am J Obstet Gynecol 2000;183:1124-1129.
3.
Kramer BW: Chorioamnionitis - new ideas from experimental models. Neonatology 2011;99:320-325.
4.
Babnik J, Stucin-Gantar I, Kornhauser-Cerar L, Sinkovec J, Wraber B, Derganc M: Intrauterine inflammation and the onset of peri-intraventricular hemorrhage in premature infants. Biol Neonate 2006;90:113-121.
5.
Lee SE, Romero R, Jung H, Park CW, Park JS, Yoon BH: The intensity of the fetal inflammatory response in intraamniotic inflammation with and without microbial invasion of the amniotic cavity. Am J Obstet Gynecol 2007;197:294.e1-294.e6.
6.
Buhimschi CS, Dulay AT, Abdel-Razq S, Zhao G, Lee S, Hodgson EJ, et al: Fetal inflammatory response in women with proteomic biomarkers characteristic of intra-amniotic inflammation and preterm birth. BJOG 2009;116:257-267.
7.
Pacora P, Chaiworapongsa T, Maymon E, Kim YM, Gomey R, Yoon BH, et al: Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. J Matern Fetal Neonatal Med 2002;11:18-25.
8.
Haque KN: Definitions of bloodstream infection in the newborn. Pediatr Crit Care Med 2005;6(suppl):S45-S49.
9.
Thomas W, Speer CP: Chorioamnionitis: important risk factor or innocent bystander for neonatal outcome. Neonatology 2011;99:177-187.
10.
Schumann RR: Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans 2011;39:989-993.
11.
Espinoza J, Romero R, Chaiworpongsa T, Kim JC, Yoshimatsu J, Edwin C, et al: Lipopolysaccharide-binding protein in microbial invasion of the amniotic cavity and human parturition. J Matern Fetal Neonatal Med 2002;12:313-321.
12.
Torbe A, Sokolowska M, Kwiatkowski S, Rzepka R, Torbe B, Czajka R: Maternal plasma lipopolysaccharide binding protein (LBP) concentrations in pregnancy complicated by preterm premature rupture of membranes. Eur J Obstet Gynecol Reprod Biol 2011;156:153-157.
13.
Gardella C, Hitti J, Martin TR, Ruzinski JT, Eschenbach D: Amniotic fluid lipopolysaccharide-binding protein and soluble CD14 as mediators of the inflammatory response in preterm labor. Am J Obstet Gynecol 2001;184:1241-1248.
14.
Behrendt D, Dembinski J, Heep A, Bartman P: Lipopolysaccharide binding protein in preterm infants. Arch Dis Child Fetal Neonatal Ed 2004;89:F551-F554.
15.
Orlikowsky TW, Trug C, Neunhoeffer F, Deperschmidt M, Eichner M, Poets CF: Lipopolysaccharide-binding protein in noninfected neonates and those with suspected early-onset bacterial infection. J Perinatol 2006;26:115-119.
16.
Pavcnik-Arnol M, Hojker S, Derganc M: Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Med 2004;30:1454-1460.
17.
Frankenburg WK, Dodds J, Archer P, Shapiro H, Bresnick B: The Denver II: a major revision and restandardisation of the Denver Developmental Screening Test. Pediatrics 1992;89:91-97.
18.
Myc A, Buck J, Gonin J, Reynolds B, Hammerling U, Emanuel D: The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol 1997;4:113-116.
19.
Pavcnik-Arnol M, Hojker S, Derganc M: Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children. Intensive Care Med 2007;33:1025-1032.
20.
Kim CJ, Yoon BH, Park SS, Kim MH, Chi JG: Acute funisitis of preterm but not term placentas is associated with severe fetal inflammatory response. Hum Pathol 2001;32:623-629.
21.
Le Rouzic V, Corona J, Zhou H: Postnatal development of hepatic innate immune response. Inflammation 2011;34:576-584.
22.
Roos T, Martin TR, Ruzinski JT, Leturcq DJ, Hillier SH, Patton DL, Eschenbach DA: Lipopolysaccharide binding protein and soluble CD14 receptor protein in amniotic fluid and cord blood in patients at term. Am J Obstet Gynecol 1997;177:1230-1237.
23.
D'Alquen D, Kramer BW, Seidenspinner S, Marx A, Berg D, Groneck P, Speer C: Activation of umbilical cord endothelial cells and fetal inflammatory response in preterm infants with chorioamnionitis and funisitis. Pediatr Res 2005;57:263-269.
24.
Batfalsky A, Lohr A, Heusen N, Neunheffer F, Orlikowsky TW: Diagnostic value of an interleukin-6 bedside test in term and preterm neonates at the time of clinical suspicion of early- and late-onset bacterial infection. Neonatology 2012;102:37-44.
25.
Malaeb S, Dammann O: Fetal inflammatory response and brain injury in the preterm newborn. J Child Neurol 2009;24:1119-1126.
26.
Leviton A, Allred EN, Kuban KC, Hecht JL, Onderdonk AB, O'Shea TM, Paneth N: Microbiologic and histologic characteristics of the extremely preterm infant's placenta predict white matter damage and later cerebral palsy. The ELGAN study. Pediatr Res 2010;67:95-101.
27.
Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al: The classical complement cascade mediates CNS synapse elimination. Cell 2007;131:1164-1178.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.